Research Article

Systematic Pan-Cancer Analysis and Experimental Verification Identify FOXA1 as an Immunological and Prognostic Biomarker in Epithelial Ovarian Cancer

Figure 8

The suppressive effects of FOXA1 silencing on EMT through TGF-beta 1 signaling pathway. (a) Predicted binding site of FOXA1 at the wild-type CTGF promoter region and the mutant CTGF promoter (-399 to -390) was present. (b) Relative luciferase activity was presented as per the ratio of the intensity of firefly luciferase to that of Renilla. (c) Western blot analysis on protein expression levels of FOXA1, CTGF, MMP-2, E-cadherin, and Snail in the siRNA-NC-, or the siRNA-FOXA1-transfected cells treated with or without TGF-β1. Quantifications of protein expressions was represented as deviation (SD) of the results from six independent replicates in each group. (d) Expressions of FOXA1, CTGF, cleaved TGF-beta 1, and EMT-associated markers including E-cadherin, vimentin, and Snail were analyzed by western blot after 48 h after the transfected cells treated with or without lithium chloride. Quantification of the representative blots was represented as deviation (SD) of the results from three independent experiment in bar graphs.
(a)
(b)
(c)
(d)